Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Ever-Expanding Customer Base for DehydraTECH Drug Delivery Platform
Lexaria Bioscience recently announced its DehydraTECH(TM) patent for pharmaceutical applications of cannabinoids to treat certain disease conditions Lexaria Bioscience’s patented DehydraTECH drug delivery platform can be used to deliver nicotine, cannabinoids and many other useful substances The company has roughly 60 patents pending in countries around the world for its DehydraTECH drug delivery platform Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is at the forefront of the development of useful biotechnology products and has played a pivotal role in developing a way to deliver substances to the brain via non-inhalation methods through the development of a novel drug delivery platform. The…